This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
A phase 1b/2 open-label study evaluating trastuzumab deruxtecan in combination with rilvegostomig and chemotherapy in patients with HER2-positive and HER2-low gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric03
Part 4
Poster
T-DXd
ASCO 2025 | May 30-June 3,2025
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy ±
pembrolizumab versus chemotherapy + trastuzumab ± pembrolizumab in first-line metastatic HER2+ gastric
or gastroesophageal junction cancer: DESTINY-Gastric05
Poster
T-DXd
ASCO 2025 | May 30-June 3,2025
ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan as first-line treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer
Poster
T-DXd
ASCO GI 2025 | January 23-25, 2025
Concordance between HER2 status by IHC and NGS in tissue and blood samples from gastric and gastroesophageal junction cancers
Poster
T-DXd
JSMO 2025 | March 6-8, 2025
Efficacy of trastuzumab deruxtecan and biomarker changes in HER2-positive gastric cancer: EN-MARK study protocol
Poster
HER3-DXd
ASCO GI 2025 | January 23-25, 2025
Phase 1/2 study of the HER3-directed antibody-drug conjugate patritumab deruxtecan (MK-1022) as monotherapy in patients with gastrointestinal cancers
Poster
Other/Multi
ACoP15 | November 10-13, 2024
Population pharmacokinetics and exposure–safety of DS-6157 in patients with advanced gastrointestinal stromal tumor
Mini-Oral
T-DXd
JSMO 2025 | March 6-8, 2025
Prognostic factors for T-DXd treatment in HER2+ unresectable advanced/recurrent gastric cancer: EN-DEAVOR sub-analysis
Poster
T-DXd
ASCO GI 2025 | January 23-25, 2025
Real-world safety of trastuzumab deruxtecan with gastric cancer: All-patient post-marketing surveillance study in Japan
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Real-world treatment patterns in patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (HER2+ aGC/GEJC) in East Asia (HER2+ GASTA)
Pages:
1 2